[go: up one dir, main page]

CA2589421A1 - Erbb3 antibodies - Google Patents

Erbb3 antibodies Download PDF

Info

Publication number
CA2589421A1
CA2589421A1 CA002589421A CA2589421A CA2589421A1 CA 2589421 A1 CA2589421 A1 CA 2589421A1 CA 002589421 A CA002589421 A CA 002589421A CA 2589421 A CA2589421 A CA 2589421A CA 2589421 A1 CA2589421 A1 CA 2589421A1
Authority
CA
Canada
Prior art keywords
erbb3
erbb2
heregulin
cell
ability
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002589421A
Other languages
French (fr)
Other versions
CA2589421C (en
Inventor
Robert Akita
Mark Sliwkowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority claimed from CA002246429A external-priority patent/CA2246429C/en
Publication of CA2589421A1 publication Critical patent/CA2589421A1/en
Application granted granted Critical
Publication of CA2589421C publication Critical patent/CA2589421C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Antibodies are disclosed which bind to ErbB3 protein and further possess any one or more of the following properties: an ability to reduce heregulin-induced formation of an ErbB2-ErbB3 protein complex in a cell which expresses ErbB2 and ErbB3; the ability to increase the binding affinity of heregulin for ErbB3 protein; and the characteristic of reducing heregulin-induced ErbB2 activation in a cell which expresses ErbB2 and ErbB3.

Claims

WHAT IS CLAIMED IS:
1. An antibody which binds to ErbB3 protein, reduces heregulin binding thereto, and reduces heregulin-induced ErbB2 activation in a cell which expresses ErbB2 and ErbB3.
CA2589421A 1996-03-27 1997-03-07 Erbb3 antibodies Expired - Lifetime CA2589421C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62403696A 1996-03-27 1996-03-27
US08/624,036 1996-03-27
CA002246429A CA2246429C (en) 1996-03-27 1997-03-07 Erbb3 antibodies

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA002246429A Division CA2246429C (en) 1996-03-27 1997-03-07 Erbb3 antibodies

Publications (2)

Publication Number Publication Date
CA2589421A1 true CA2589421A1 (en) 1997-10-02
CA2589421C CA2589421C (en) 2012-12-18

Family

ID=38326392

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2589421A Expired - Lifetime CA2589421C (en) 1996-03-27 1997-03-07 Erbb3 antibodies

Country Status (1)

Country Link
CA (1) CA2589421C (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9085622B2 (en) 2010-09-03 2015-07-21 Glaxosmithkline Intellectual Property Development Limited Antigen binding proteins

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9085622B2 (en) 2010-09-03 2015-07-21 Glaxosmithkline Intellectual Property Development Limited Antigen binding proteins

Also Published As

Publication number Publication date
CA2589421C (en) 2012-12-18

Similar Documents

Publication Publication Date Title
CA2246429A1 (en) Erbb3 antibodies
CA2172376A1 (en) Antibodies to cd40
WO1997037029B1 (en) MONOCLONAL ANTIBODIES SPECIFIC FOR THE PLATELET DERIVED GROWTH FACTOR β RECEPTOR AND METHODS OF USE THEREOF
CA2109815A1 (en) Antibody preparation
ATE412432T1 (en) INTERNALIZING ERBB2 ANTIBODIES
WO2005061547A3 (en) Bispecific antibodies
AU2910197A (en) Antibodies to the ed-b domain of fibronectin, their construction and uses
CA2387267A1 (en) Methods of optimizing antibody variable region binding affinity
EP0741868A1 (en) Immunoassays for prostate specific antigen
WO1991012023A3 (en) Hybrid reagents capable of selectively releasing molecules into cells
CA2149120A1 (en) Monoclonal antibody which specifically binds to tumor vascular endothelium and uses thereof
CA2178642A1 (en) Metal ion-ligand coordination complexes, antibodies directed thereto, and assays using such antibodies
WO1996027665A3 (en) Neuron-restrictive silencer factor proteins
CA2348026A1 (en) Antibodies against semp1, methods for their production and uses thereof
EP0227440A3 (en) Immunoassay for creatine kinase mb using bound and soluble antibodies
AU6171894A (en) Preparation of photoprotein conjugates and methods of use thereof
WO1998022510A3 (en) Methods for the production of chicken monoclonal antibodies
WO2023230626A3 (en) Ph-selective anti-cd3 antibodies and use of the same
EP1510579A3 (en) Use of heregulin as an epithelial cell growth factor
CA2219931A1 (en) Stabilized standards and calibrators
AU5301196A (en) Method for stimulating an immune response
CA2589421A1 (en) Erbb3 antibodies
NZ336781A (en) Fibronectin binding protein compositions, antibodies thereto, and methods of use
CA2163868A1 (en) Monoclonal anti-idiotypic anti-ca125 antibodies and pharmaceutical compositions containing them
WO1999025734A3 (en) Th2 CELL DEPLETION; COMPOSITIONS; METHODS

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20170307